Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005596 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,076
- Enrollment target
NCT00005596 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 1,076 participants.
The verdict
NCT00005596, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,076 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG leucovorin calcium
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,076 participants |
| Start Date | 2000-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005596
The ClinicalTrials.gov registry entry for NCT00005596 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,076 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005596 about?
NCT00005596 is a clinical study titled "Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This rando...
What is the current status of trial NCT00005596?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,076 participants. The study started on 2000-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00005596?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), leucovorin calcium (DRUG), cytarabine (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005596?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.